New Jersey-based medical technology company BD (Becton, Dickinson and Company) has appointed Dr Ellen Strahlman to the newly created role of chief medical officer and senior VP, research and development.
Dr Strahlman joins the firm from GlaxoSmithKline (GSK), which she joined in 2008, serving first as chief medical officer, and then senior medical advisor in the office of the CEO and global head of neglected tropical diseases.
Prior to her time with GSK, Dr Strahlman held executive leadership roles at Merck & Co, Novartis, Pfizer and Bausch & Lomb.
In her new role at BD Dr Strahlman will oversee the company’s medical affairs and research and development functions.
“I am very pleased that Dr Strahlman will be joining BD at a time when we are strategically focused on driving growth through innovation and customer focus,” said BD’s CEO Vincent Forlenza. “She brings extensive experience as a senior physician and leader in the pharmaceutical and medical device industries, and her patient-centric approach aligns with our focus on providing innovative solutions to address the healthcare needs of customers and patients.”
Headquartered in Franklin Lakes, New Jersey, BD develops, manufactures and sells medical devices, instrument systems and reagents.